Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
As off-label use continues to expand, particularly among patients with obesity or insulin resistance, our findings suggest GLP-1based therapies may warrant consideration as an adjunct to insulin in carefully selected patients. Advertisement Advertisement New service for patients with diabetes will make annual screening more convenient Association revises criteria for the diagnosis and resolution of severe conditions What to consider in the management of euglycemic DKA Less than 50% of patients with diabetes get appropriate ophthalmic screening through primary care referrals Familiarity will enhance its accessibility for patients with diabetes New study counters earlier findings linking drugs with eye disease Study highlights the value of quantitative ultra-widefield angiography Longevity in healthcare, personal experiences may provide caregivers with false sense of confidence
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
HCPCS K-level: Confirm K-level documentation supports the L-code tier billed for prosthetic devices
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
Ahrn B
